Adjunctive corticosteroids in non-HIV immunocompromised patients with Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis
Therapeutic Advances in Infectious Disease · 2026-08 · 13
DOI: 10.1177/20499361261468451 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Therapeutic Advances in Infectious Disease, online erschienen am 04.08.2026. Verfasst von Gustavo Rosales-Chavez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nuevo Hospital Civil de Guadalajara "Dr. Juan I. Menchaca," Guadalajara, Jalisco, Mexico. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Pneumocystis jirovecii pneumonia (PJP) in non-HIV immunocompromised adults carries 30%–60% mortality. Adjunctive corticosteroids are standard in HIV-PJP but remain contested in non-HIV PJP.
Objectives
To determine whether adjunctive corticosteroids reduce mortality and invasive mechanical ventilation (IMV) in non-HIV PJP, and whether effect estimates differ between randomized and observational study designs.
Design
Systematic review and meta-analysis. Data sources and methods: Six databases and two trial registers were searched from inception to February 7, 2026. Randomized and observational studies comparing adjunctive corticosteroids versus no corticosteroids or placebo in non-HIV adults with PJP were eligible. Random-effects meta-analyses (restricted maximum likelihood) of two co-primary outcomes included subgroup, sensitivity, E -value, and Grading of Recommendations Assessment analyses.
Results
Twenty-eight studies were included (one randomized controlled trial (RCT), 27 observational; ∼ 5300 patients): 22 contributed corticosteroid-versus-no-corticosteroid comparisons and six contributed dose-comparison data only. Evidence was discordant by design (interaction p = 0 . 006 ): the RCT showed lower IMV (hazard ratio (HR) 0.36, 95% CI 0.14–0.90) and lower 90-day mortality (HR 0.59, 0.37–0.93); regression-adjusted observational studies suggested harm (odds ratio (OR) 1.56, 1.10–2.22); propensity-based estimates were null-compatible. Pre-specified mortality pools were non-significant short-term (OR 1.22, 0.88–1.70) and intermediate-term (OR 1.39, 0.85–2.29). Secondary infections ( k = 4 ): OR 1.04 (0.63–1.72); RCT 0.59 (0.32–1.06). E -values for RCT effects (3.44 IMV; 2.24 mortality) exceeded the 1.81 E -value of the adjusted observational mortality pool. Certainty was very low for pooled mortality and moderate for RCT outcomes.
Conclusion
Reliable inference rests on the single RCT rather than the pooled observational estimate, which is discordant by design and most consistent with confounding by indication. In the RCT, corticosteroids did not significantly reduce 28-day mortality but lowered IMV and 90-day mortality and sped respiratory recovery, without clear excess secondary infections (low certainty). Corticosteroids may be considered for severe respiratory failure using the PIC (ClinicalTrials.gov NCT02944045) protocol; adequately powered confirmatory trials are needed.
Trial registration
PROSPERO CRD420261304396.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nuevo Hospital Civil de Guadalajara "Dr. Juan I. Menchaca," Guadalajara, Jalisco, Mexico.
- División Salud, Centro Universitario de Tlajomulco, Universidad de Guadalajara, Tlajomulco de Zúñiga, Jalisco, Mexico.
- Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde," Guadalajara, Jalisco, Mexico.
- Hospital Civil de Oriente, Tonalá, Jalisco, Mexico.
- Hospitales Puerta de Hierro Colima, Colima, Colima, Mexico.
- Centro Respiratorio de Occidente, Guadalajara, Jalisco, Mexico.
ORCID-Profile: Gustavo Rosales-Chavez, Pedro Martínez-Ayala, Mauricio Alfredo Ambriz-Alarcón, Brian Rafael Rubio-Mora, Judith Carolina De Arcos-Jiménez, Ana María López-Yáñez, Alejandro Marín-Castañeda-Barón, Andrés Alejandro Briseño-Hernández, José Rafael Villafán-Bernal, Jaime Alejandro Sánchez-Gutiérrez, Jaime Briseno-Ramirez
Zitieren
APA
Rosales-Chavez, G., Martínez-Ayala, P., Ambriz-Alarcón, M. A., Rubio-Mora, B. R., Arcos-Jiménez, J. C., López-Yáñez, A. M., Marín-Castañeda-Barón, A., Briseño-Hernández, A. A., Villafán-Bernal, J. R., Sánchez-Gutiérrez, J. A., & Briseno-Ramirez, J. (2026). Adjunctive corticosteroids in non-HIV immunocompromised patients with Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Therapeutic Advances in Infectious Disease, 13. https://doi.org/10.1177/20499361261468451
Vancouver
Rosales-Chavez G, Martínez-Ayala P, Ambriz-Alarcón MA, Rubio-Mora BR, Arcos-Jiménez JC, López-Yáñez AM, et al. Adjunctive corticosteroids in non-HIV immunocompromised patients with Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Therapeutic Advances in Infectious Disease. 2026;13. doi:10.1177/20499361261468451
BibTeX
@article{RosalesChavez2026,
author = {Rosales-Chavez, Gustavo and Martínez-Ayala, Pedro and Ambriz-Alarcón, Mauricio Alfredo and Rubio-Mora, Brian Rafael and Arcos-Jiménez, Judith Carolina De and López-Yáñez, Ana María and Marín-Castañeda-Barón, Alejandro and Briseño-Hernández, Andrés Alejandro and Villafán-Bernal, José Rafael and Sánchez-Gutiérrez, Jaime Alejandro and Briseno-Ramirez, Jaime},
title = {Adjunctive corticosteroids in non-HIV immunocompromised patients with Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis},
journal = {Therapeutic Advances in Infectious Disease},
year = {2026},
volume = {13},
doi = {10.1177/20499361261468451}
}
EUVIMED